These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective. Nolan JD; Johnston IM; Walters JR Expert Rev Gastroenterol Hepatol; 2013 Jan; 7(1):49-56. PubMed ID: 23265149 [TBL] [Abstract][Full Text] [Related]
7. Targeting farnesoid X receptor for liver and metabolic disorders. Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816 [TBL] [Abstract][Full Text] [Related]
8. Novel Aspects in the Management of Cholestatic Liver Diseases. Chazouillères O Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387 [TBL] [Abstract][Full Text] [Related]
9. Role of farnesoid X receptor in cholestasis. Yuan ZQ; Li KW J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832 [TBL] [Abstract][Full Text] [Related]
10. Cross-talk between bile acids and intestinal microbiota in host metabolism and health. Nie YF; Hu J; Yan XH J Zhejiang Univ Sci B; 2015 Jun; 16(6):436-46. PubMed ID: 26055905 [TBL] [Abstract][Full Text] [Related]
11. Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis. Katafuchi T; Makishima M Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682726 [TBL] [Abstract][Full Text] [Related]
12. Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Ho PP; Steinman L Proc Natl Acad Sci U S A; 2016 Feb; 113(6):1600-5. PubMed ID: 26811456 [TBL] [Abstract][Full Text] [Related]
13. Bile acids mediated potential functional interaction between FXR and FATP5 in the regulation of Lipid Metabolism. Kumari A; Pal Pathak D; Asthana S Int J Biol Sci; 2020; 16(13):2308-2322. PubMed ID: 32760200 [TBL] [Abstract][Full Text] [Related]
14. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. Zollner G; Marschall HU; Wagner M; Trauner M Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856 [TBL] [Abstract][Full Text] [Related]
15. Bile acid-mediated control of liver triglycerides. Fuchs C; Claudel T; Trauner M Semin Liver Dis; 2013 Nov; 33(4):330-42. PubMed ID: 24222091 [TBL] [Abstract][Full Text] [Related]
16. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532 [TBL] [Abstract][Full Text] [Related]
17. Endocrine functions of bile acids. Houten SM; Watanabe M; Auwerx J EMBO J; 2006 Apr; 25(7):1419-25. PubMed ID: 16541101 [TBL] [Abstract][Full Text] [Related]
18. Role of bile acids and bile acid receptors in metabolic regulation. Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757 [TBL] [Abstract][Full Text] [Related]
19. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753 [TBL] [Abstract][Full Text] [Related]
20. Effect of different bile acids on the intestine through enterohepatic circulation based on FXR. Xiang J; Zhang Z; Xie H; Zhang C; Bai Y; Cao H; Che Q; Guo J; Su Z Gut Microbes; 2021; 13(1):1949095. PubMed ID: 34313539 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]